Myfortic + Decortin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uveitis, Intermediate
Conditions
Uveitis, Intermediate
Trial Timeline
Mar 1, 2010 → Oct 1, 2015
NCT ID
NCT01092533About Myfortic + Decortin
Myfortic + Decortin is a phase 3 stage product being developed by Novartis for Uveitis, Intermediate. The current trial status is completed. This product is registered under clinical trial identifier NCT01092533. Target conditions include Uveitis, Intermediate.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01092533 | Phase 3 | Completed |
Competing Products
20 competing products in Uveitis, Intermediate
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| triamcinolone acetonide (Triesence®) | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA Suprachoriodal Injection | Clearside Biomedical | Phase 3 | 69 |
| Baricitinib + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 85 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Approved | 85 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| AIN457 | Novartis | Phase 3 | 77 |
| Myfortic | Novartis | Pre-clinical | 23 |
| AIN457 + AIN457 + Placebo AIN457 | Novartis | Phase 3 | 77 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AEB071 | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |